SCHEMBL25783758

SCHEMBL25783758

c1ccc(-c2cc(OCCn3cncn3)c3[nH]c4ccccc4c3c2)cc1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SMN1; SMN2 Q16637 6/20 0.55
▸ HTT P42858 1/20 0.55
▸ MAPT P10636 5/20 0.47
▸ ALDH1A1 P00352 5/20 0.47
▸ TP53 P04637 4/20 0.47
▸ KDM4E B2RXH2 5/20 0.47
▸ LMNA P02545 3/20 0.47
▸ MEN1 O00255 1/20 0.47
▸ KMT2A Q03164 1/20 0.47
▸ NPC1 O15118 3/20 0.44
▸ RAB9A P51151 3/20 0.44
▸ MAPK1 P28482 2/20 0.43
▸ TSHR P16473 1/20 0.40
▸ TDP1 Q9NUW8 1/20 0.40
▸ CYP19A1 P11511 1/20 0.39
▸ PKM P14618 1/20 0.39
▸ EGLN3 Q9H6Z9 1/20 0.39
▸ NFKB1 P19838 1/20 0.38
▸ NFKB2 Q00653 1/20 0.38
▸ RELA Q04206 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23875449 0.86 SMN1; SMN2 (0.47) SMN1; SMN2HTTMAPTALDH1A1TP53
SCHEMBL25785696 0.86 SMN1; SMN2 (0.47) SMN1; SMN2HTTMAPTALDH1A1TP53
SCHEMBL23875533 0.81 SMN1; SMN2 (0.47) SMN1; SMN2HTTMAPTALDH1A1TP53
SCHEMBL23875628 0.77 ALDH1A1 (0.44) SMN1; SMN2HTTMAPTALDH1A1TP53
SCHEMBL23875516 0.76 KDM4E (0.53) SMN1; SMN2HTTMAPTALDH1A1TP53
SCHEMBL23875457 0.73 ALDH1A1 (0.48) SMN1; SMN2HTTMAPTALDH1A1TP53
SCHEMBL25798557 0.72 CYP19A1 (0.43) SMN1; SMN2HTTMAPTALDH1A1TP53
SCHEMBL25783423 0.72 SMN1; SMN2 (0.52) SMN1; SMN2HTTMAPTALDH1A1TP53
SCHEMBL30060844 0.70 MAPT (0.40) SMN1; SMN2HTTMAPTALDH1A1TP53
SCHEMBL23875524 0.70 MAPT (0.40) SMN1; SMN2HTTMAPTALDH1A1TP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230174485-A1 LIPOXYGENASE INHIBITORS SRI INTERNATIONAL (US) 2023-06-08 — — US disclosed
US-20230174485-A1 LIPOXYGENASE INHIBITORS SRI INTERNATIONAL (US) 2023-06-08 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230174485-A1 LIPOXYGENASE INHIBITORS ALOX15B, ALOX12, ALOX15 SMN1; SMN2 1035/4885HTT 777/4885MAPT 1601/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback